Itonis, Inc. (ITNS) Signs Exploratory Analysis Tri
Post# of 1230
LAGUNA HILLS, CA--(Marketwired - Apr 16, 2014) - Itonis, Inc. (PINKSHEETS: ITNS) today announced that it has signed an agreement with Valley Organics Inc. to start a 30-day "Exploratory Analysis Trial" for the Company's cannabinoid-based product that is presently named as its Cloud9 project.
Valley Organics Inc. is not a wholly owned asset of nor affiliated with Latteno Food Corp.
The initial 200mg Cloud9 product is not for sale or distribution, it is only for the Exploratory Analysis Trial purposes only.
The Company expects that upon Valley Organics' completion of the Exploratory Analysis Trial, the Company will be in a position to manufacture the Cloud9 product for distribution.
The Company has been developing the Cloud9 product as a unique sublingual that dissolves under the tongue as a convenient delivery method. The manufacturing of the Cloud9 product will use a Supercritical CO(2) Extraction process to extract cannabinoids ("CBDs" from hemp oil within lawful parameters. The Company plans on making Cloud9 available in a unit range of 100 - 200 mg.
About Valley Organics Inc.
Southern California-owned and licensed medical marijuana co-op and transporting. The specific purpose of this corporation is to collectively facilitate medical marijuana cultivation and transactions by and between qualified patient members of this corporation and/or primary caregiver members who have the oral or written approval or recommendation of a licensed physician, as permitted and authorized by the Compassionate Use Act of 1996 (Health and Safety Code section 11362.5) and the Medical Marijuana Program Act (Health and Safety Code sections 11362.7 - 11362.83).